Adenovirus‑mediated REIC/Dkk‑3 gene therapy: Development of an autologous cancer vaccination therapy (Review)

Watanabe,Masami; Nasu,Yasutomo; Kumon,Hiromi

doi:10.3892/ol.2013.1777

Adenovirus‑mediated REIC/Dkk‑3 gene therapy: Development of an autologous cancer vaccination therapy (Review)

Authors:
- Masami Watanabe
- Yasutomo Nasu
- Hiromi Kumon
View Affiliations

Affiliations: Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Okayama 700‑8558, Japan, Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Okayama 700‑8558, Japan
Published online on: December 27, 2013 https://doi.org/10.3892/ol.2013.1777
Pages: 595-601

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Reduced expression in immortalized cells (REIC)/Dickkopf (Dkk)‑3 is a tumor suppressor and therapeutic gene and has been studied with respect to the application of cancer gene therapy. Our previous studies demonstrated that the intratumoral injection of an adenovirus vector carrying the human REIC/Dkk‑3 gene (Ad‑REIC) suppresses tumor growth in mouse models of prostate, breast and testicular cancer and malignant mesothelioma. The mechanisms underlying these antitumor therapeutic effects have only been clarified recently. It has been demonstrated that Ad‑REIC treatment inhibits cancer progression via the upregulation of systemic anticancer immunity. Under experimental conditions, autologous cancer vaccination via cancer‑specific apoptosis and anticancer immune activation is a possible therapeutic mechanism. The robust anticancer effects observed in previous preclinical studies support the clinical utility of Ad‑REIC. At present, a phase I‑IIa study of Ad‑REIC gene therapy in prostate cancer patients is ongoing. The current study reviews the observations of previous fundamental studies and summarizes the anticancer mechanisms of intratumoral Ad‑REIC treatment in terms of cancer vaccination.

View Figures

View References

1	Schlom J: Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 104:599–613. 2012. View Article : Google Scholar : PubMed/NCBI
2	Drake CG: Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 10:580–593. 2010. View Article : Google Scholar : PubMed/NCBI
3	de Gruijl TD, van den Eertwegh AJ, Pinedo HM and Scheper RJ: Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother. 57:1569–1577. 2008.PubMed/NCBI
4	Yamada A, Sasada T, Noguchi M and Itoh K: Next-generation peptide vaccines for advanced cancer. Cancer Sci. 104:15–21. 2013. View Article : Google Scholar : PubMed/NCBI
5	Sugimoto M, Watanabe M, Kaku H, Li SA, Noguchi H, Ueki H, Sakaguchi M, Huh NH, Nasu Y and Kumon H: Preclinical biodistribution and safety study of reduced expression in immortalized cells/Dickkopf-3-encoding adenoviral vector for prostate cancer gene therapy. Oncol Rep. 28:1645–1652. 2012.
6	Hirata T, Watanabe M, Kaku H, Kobayashi Y, Yamada H, Sakaguchi M, Takei K, Huh NH, Nasu Y and Kumon H: REIC/Dkk-3-encoding adenoviral vector as a potentially effective therapeutic agent for bladder cancer. Int J Oncol. 41:559–564. 2012.PubMed/NCBI
7	Shirakawa T: Clinical trial design for adenoviral gene therapy products. Drug News Perspect. 22:140–145. 2009. View Article : Google Scholar : PubMed/NCBI
8	Lipinski KS, Pelech S, Mountain A, Irvine AS, Kraaij R, Bangma CH, Mills KH and Todryk SM: Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity. Cancer Immunol Immunother. 55:347–354. 2006. View Article : Google Scholar
9	Tsuji T, Miyazaki M, Sakaguchi M, Inoue Y and Namba M: A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. Biochem Biophys Res Commun. 268:20–24. 2000. View Article : Google Scholar : PubMed/NCBI
10	Nozaki I, Tsuji T, Iijima O, Ohmura Y, Andou A, Miyazaki M, Shimizu N and Namba M: Reduced expression of REIC/Dkk-3 gene in non-small cell lung cancer. Int J Oncol. 19:117–121. 2001.PubMed/NCBI
11	Kurose K, Sakaguchi M, Nasu Y, Ebara S, Kaku H, Kariyama R, Arao Y, Miyazaki M, Tsushima T, Namba M, Kumon H and Huh NH: Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. J Urol. 171:1314–1318. 2004. View Article : Google Scholar : PubMed/NCBI
12	Hsieh SY, Hsieh PS, Chiu CT and Chen WY: Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene. 23:9183–9189. 2004.PubMed/NCBI
13	Abarzua F, Sakaguchi M, Takaishi M, Nasu Y, Kurose K, Ebara S, Miyazaki M, Namba M, Kumon H and Huh NH: Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. Cancer Res. 65:9617–9622. 2005. View Article : Google Scholar
14	Sato H, Suzuki H, Toyota M, Nojima M, Maruyama R, Sasaki S, Takagi H, Sogabe Y, Sasaki Y, Idogawa M, Sonoda T, et al: Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis. 28:2459–2466. 2007. View Article : Google Scholar : PubMed/NCBI
15	Yang B, Du Z, Gao YT, Lou C, Zhang SG, Bai T, Wang YJ and Song WQ: Methylation of Dickkopf-3 as a prognostic factor in cirrhosis-related hepatocellular carcinoma. World J Gastroenterol. 16:755–763. 2010. View Article : Google Scholar : PubMed/NCBI
16	Veeck J and Dahl E: Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta. 1825:18–28. 2012.PubMed/NCBI
17	Hayashi T, Asano H, Toyooka S, Tsukuda K, Soh J, Shien T, Taira N, Maki Y, Tanaka N, Doihara H, Nasu Y, Huh NH and Miyoshi S: DNA methylation status of REIC/Dkk-3 gene in human malignancies. J Cancer Res Clin Oncol. 138:799–809. 2012. View Article : Google Scholar : PubMed/NCBI
18	Tanimoto R, Abarzua F, Sakaguchi M, Takaishi M, Nasu Y, Kumon H and Huh NH: REIC/Dkk-3 as a potential gene therapeutic agent against human testicular cancer. Int J Mol Med. 19:363–368. 2007.PubMed/NCBI
19	Kashiwakura Y, Ochiai K, Watanabe M, Abarzua F, Sakaguchi M, Takaoka M, Tanimoto R, Nasu Y, Huh NH and Kumon H: Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. Cancer Res. 68:8333–8341. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kawasaki K, Watanabe M, Sakaguchi M, Ogasawara Y, Ochiai K, Nasu Y, Doihara H, Kashiwakura Y, Huh NH, Kumon H and Date H: REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer. Cancer Gene Ther. 16:65–72. 2009. View Article : Google Scholar : PubMed/NCBI
21	Sakaguchi M, Huh NH and Namba M: A novel tumor suppressor, REIC/Dkk-3 gene identified by our in vitro transformation model of normal human fibroblasts works as a potent therapeutic anti-tumor agent. Adv Exp Med Biol. 720:209–215. 2011. View Article : Google Scholar
22	Zhang K, Watanabe M, Kashiwakura Y, Li SA, Edamura K, Huang P, Yamaguchi K, Nasu Y, Kobayashi Y, Sakaguchi M, Ochiai K, et al: Expression pattern of REIC/Dkk-3 in various cell types and the implications of the soluble form in prostatic acinar development. Int J Oncol. 37:1495–1501. 2010.PubMed/NCBI
23	Kobayashi K, Ouchida M, Tsuji T, Hanafusa H, Miyazaki M, Namba M, Shimizu N and Shimizu K: Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene. 282:151–158. 2002. View Article : Google Scholar : PubMed/NCBI
24	Pinho S and Niehrs C: Dkk3 is required for TGF-beta signaling during Xenopus mesoderm induction. Differentiation. 75:957–967. 2007.PubMed/NCBI
25	Onai T, Takai A, Setiamarga DH and Holland LZ: Essential role of Dkk3 for head formation by inhibiting Wnt/β-catenin and Nodal/Vg1 signaling pathways in the basal chordate amphioxus. Evol Dev. 14:338–350. 2012.PubMed/NCBI
26	Kawano Y, Kitaoka M, Hamada Y, Walker MM, Waxman J and Kypta RM: Regulation of prostate cell growth and morphogenesis by Dickkopf-3. Oncogene. 25:6528–6537. 2006. View Article : Google Scholar : PubMed/NCBI
27	Romero D, Kawano Y, Bengoa N, Walker MM, Maltry N, Niehrs C, Waxman J and Kypta R: Downregulation of Dickkopf-3 disrupts prostate acinar morphogenesis through TGF-β/Smad signaling. J Cell Sci. 126:1858–1867. 2013.PubMed/NCBI
28	Karamariti E, Margariti A, Winker B, Wang X, Hong X, Baban D, Ragoussis J, Huang Y, Han JD, Wong MM, Sag CM, et al: Smooth muscle cells differentiated from reprogrammed embryonic lung fibroblasts through DKK3 signalling are potent for tissue engineering of vascular grafts. Circ Res. 112:1433–1443. 2013. View Article : Google Scholar
29	Nakamura RE and Hackam AS: Analysis of Dickkopf3 interactions with Wnt signaling receptors. Growth Factors. 28:232–242. 2010. View Article : Google Scholar : PubMed/NCBI
30	Lee EJ, Jo M, Rho SB, Park K, Yoo YN, Park J, Chae M, Zhang W and Lee JH: Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Cancer. 124:287–297. 2009. View Article : Google Scholar : PubMed/NCBI
31	Ochiai K, Watanabe M, Ueki H, Huang P, Fujii Y, Nasu Y, Noguchi H, Hirata T, Sakaguchi M, Huh NH, Kashiwakura Y, et al: Tumor suppressor REIC/Dkk-3 interacts with the dynein light chain, Tctex-1. Biochem Biophys Res Commun. 412:391–395. 2011. View Article : Google Scholar : PubMed/NCBI
32	Lin CL, Wang JY, Ko JY, Huang YT, Kuo YH and Wang FS: Dickkopf-1 promotes hyperglycemia-induced accumulation of mesangial matrix and renal dysfunction. J Am Soc Nephrol. 21:124–135. 2010. View Article : Google Scholar : PubMed/NCBI
33	Watanabe M, Kashiwakura Y, Huang P, Ochiai K, Futami J, Li SA, Takaoka M, Nasu Y, Sakaguchi M, Huh NH and Kumon H: Immunological aspects of REIC/Dkk-3 in monocyte differentiation and tumor regression. Int J Oncol. 34:657–663. 2009. View Article : Google Scholar : PubMed/NCBI
34	Cunningham NS, Paralkar V and Reddi AH: Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. Proc Natl Acad Sci USA. 89:11740–11744. 1992. View Article : Google Scholar
35	Manicassamy S, Reizis B, Ravindran R, Nakaya H, Salazar-Gonzalez RM, Wang YC and Pulendran B: Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science. 329:849–853. 2010. View Article : Google Scholar
36	Valencia J, Hernández-López C, Martínez VG, Hidalgo L, Zapata AG, Vicente Á, Varas A and Sacedón R: Wnt5a skews dendritic cell differentiation to an unconventional phenotype with tolerogenic features. J Immunol. 187:4129–4139. 2011. View Article : Google Scholar : PubMed/NCBI
37	Van den Bossche J, Malissen B, Mantovani A, De Baetselier P and Van Ginderachter JA: Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. Blood. 119:1623–1633. 2012.PubMed/NCBI
38	Niwa H, Yamamura K and Miyazaki J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 108:193–199. 1991. View Article : Google Scholar : PubMed/NCBI
39	Araki K, Araki M, Miyazaki J and Vassalli P: Site-specific recombination of a transgene in fertilized eggs by transient expression of Cre recombinase. Proc Natl Acad Sci USA. 92:160–164. 1995. View Article : Google Scholar : PubMed/NCBI
40	Sakaguchi M, Kataoka K, Abarzua F, Tanimoto R, Watanabe M, Murata H, Than SS, Kurose K, Kashiwakura Y, Ochiai K, Nasu Y, et al: Overexpression of REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7. J Biol Chem. 284:14236–14244. 2009. View Article : Google Scholar : PubMed/NCBI
41	Mizobuchi Y, Matsuzaki K, Kuwayama K, Kitazato K, Mure H, Kageji T and Nagahiro S: REIC/Dkk-3 induces cell death in human malignant glioma. Neuro Oncol. 10:244–253. 2008. View Article : Google Scholar : PubMed/NCBI
42	Edamura K, Nasu Y, Takaishi M, Kobayashi T, Abarzua F, Sakaguchi M, Kashiwakura Y, Ebara S, Saika T, Watanabe M, Huh NH and Kumon H: Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model. Cancer Gene Ther. 14:765–772. 2007. View Article : Google Scholar : PubMed/NCBI
43	Than SS, Kataoka K, Sakaguchi M, Murata H, Abarzua F, Taketa C, Du G, Yashiro M, Yanagihara K, Nasu Y, Kumon H and Huh NH: Intraperitoneal administration of an adenovirus vector carrying REIC/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma. Oncol Rep. 25:989–995. 2011.
44	Naume B and Espevik T: Effects of IL-7 and IL-2 on highly enriched CD56⁺ natural killer cells. A comparative study. J Immunol. 147:2208–2214. 1991.PubMed/NCBI